2024
Circumscribed Masses
Harigopal M, Raghu M, Pham R, Rende A, Podany P, Andrejeva L. Circumscribed Masses. 2024, 11-55. DOI: 10.1007/978-3-031-65711-5_2.Peer-Reviewed Original ResearchTerminal duct lobular unitsEncapsulated papillary carcinomaInvasive ductal carcinomaCircumscribed massFibroepithelial neoplasmsStromal componentsScreening mammographyPhyllodes tumorFibroepithelial lesionsPapillary carcinomaDuctal carcinomaInvasive carcinomaComplicated cystsCellular fibroadenomaHigh-grade invasive ductal carcinomaBI-RADSDuctal carcinoma in situOuter layer of myoepithelial cellsAggressive breast malignancyBasal-like carcinomasBenign fibroepithelial lesionsBenign fibroepithelial neoplasmBorderline phyllodes tumorMalignant phyllodes tumorSmooth muscle metaplasiaSpiculated Masses
Harigopal M, Andrejeva L, Lanjewar S, Podany P. Spiculated Masses. 2024, 127-158. DOI: 10.1007/978-3-031-65711-5_5.Peer-Reviewed Original ResearchInvasive ductal carcinomaInvasive lobular carcinomaDuctal carcinoma in situLobular carcinomaDuctal carcinomaSpiculated massesTumor cellsBenign entitySclerosing adenosisCorrelation of imaging findingsDesmoplastic stromal responseDiscohesive tumor cellsCore needle biopsyPseudoangiomatous stromal hyperplasiaCarcinoma in situInvasive mammary carcinomaFalse-negative mammogramsGranular cell tumorInvasive tumor cellsDiabetic mastopathyMucinous carcinomaStromal hyperplasiaInvasive cancerPleomorphic calcificationsDesmoplastic stromaArchitectural Distortions
Butler R, Durand M, Lanjevar S, Podany P, Andrejeva L, Harigopal M. Architectural Distortions. 2024, 185-207. DOI: 10.1007/978-3-031-65711-5_7.Peer-Reviewed Original ResearchInvasive lobular carcinomaLikelihood of malignancyRadial sclerosing lesionsLobular carcinomaSclerosing lesionsTubular carcinomaArchitectural distortionBenign entityDegree of proliferative changeRadial scar/complex sclerosing lesionDuctal carcinoma in situCarcinoma in situInvasive ductal carcinomaChance of malignancyIncidental microscopic findingAbsence of enhancementPost-contrast imagesMyoepithelial cell layerEntrapped glandsField digital mammographyDiscohesive cellsSonographic correlateDuctal carcinomaInvasive carcinomaPalpable massClinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer.
Sun T, Golestani R, Zhan H, Krishnamurti U, Harigopal M, Zhong M, Liang Y. Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer. International Journal Of Surgical Pathology 2024, 10668969241256109. PMID: 38839260, DOI: 10.1177/10668969241256109.Peer-Reviewed Original ResearchBreast cancerCopy number amplificationClinicopathological characteristicsAssociation with <i>TP53</i> mutation. InAssociated with invasive ductal carcinomaEstrogen receptor (ER)-negativeDisease-free survival timeGene copy number amplificationC-myc immunostainingNon-amplified tumorsTP53</i> mutationsTriple-negative statusMetastatic breast cancerInvasive ductal carcinomaMYC protein overexpressionBreast cancer patientsTriple-negativeDuctal carcinomaClinicopathological featuresGenetic abnormalitiesClinical dataImmunohistochemical studiesCancer patientsProtein overexpressionSurvival time
2022
AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers
Lerner G, Tang H, Singh K, Golestani R, St Claire S, Humphrey P, Lannin D, Janostiak R, Harigopal M. AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers. Clinical Breast Cancer 2022, 23: 199-210. PMID: 36577560, DOI: 10.1016/j.clbc.2022.11.012.Peer-Reviewed Original ResearchConceptsInvasive ductal carcinomaTriple-negative breast cancerHigh histologic gradeApocrine differentiationAMACR expressionEstrogen receptorApocrine DCISER-/PRHistologic gradeProgesterone receptorApocrine featuresBreast cancerHuman epidermal growth factor 2 (HER2) statusLack of ERDistant metastasis-free survivalDiagnostic markerInitial N stageLack estrogen receptorApocrine breast cancerLymph node metastasisNegative breast cancerAndrogen receptor mRNACoA racemase expressionBenign breast tissueBreast cancer cohort
2020
High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers
Yoon EC, Wilson P, Zuo T, Pinto M, Cole K, Harigopal M. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers. Human Pathology 2020, 102: 13-22. PMID: 32565323, DOI: 10.1016/j.humpath.2020.06.004.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNon-TNBC casesFrequency of p16TNBC casesAndrogen receptorBreast cancerTissue microarrayAggressive clinical courseAndrogen receptor expressionInvasive ductal carcinomaHistologic grade 3Basal-like breast cancer subtypeNovel prognostic markerBreast cancer subtypesExpression of p16Clinical courseCytokeratin 5/6Ductal carcinomaPrognostic markerReceptor expressionRoutine biomarkersSignificant statistical differenceClinical dataGrade 3Cancer subtypes